In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Kura Oncology’s promising developments. The company is nearing a commercial stage with a robust cash position, bolstered by milestone payments from its partner, Kyowa Kirin. This financial strength is expected to support the ziftomenib AML program through its upcoming milestones, including potential commercialization.
Furthermore, Kura’s ziftomenib shows a favorable risk-benefit profile, with strong efficacy and safety advantages over competitors. The drug’s simplicity in dosing and lack of drug-drug interactions enhance its market potential. Additionally, the ongoing trials and anticipated data releases further strengthen the outlook for Kura Oncology, making it a compelling investment opportunity.
In another report released on October 26, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.